http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H04128231-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05ff905fdc49089f5f25746eaeb40190
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
filingDate 1990-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_620b1599762ce634012e5c62858f81ef
publicationDate 1992-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H04128231-A
titleOfInvention Treatment of indulgence of cocaine and heroin by dermally delivering buprenorphine
abstract PURPOSE: To treat the indulgence of cocaine and heroin by dermally administering an effective amount of buprenorphine to maintain the blood level of the active ingredient at a constant and harmonized level. n CONSTITUTION: Buprenorphine, the highly lipophilic ring-C-bridge oripavine of thebaine of the formula, or a pharmaceutically acceptable salt thereof is topically applied to a patient indulged in cocaine and heroin as a dermal adhesive plaster containing the compound in an amount of 25-100mg or as a cream, ointment, etc., containing the compound in an amount of 0.1-20wt.%, to maintain the level of the buprenorphine in the blood of a patient at 0.1-100ng, especially 0.6-6ng, per ml of the plasma. The adhesive plaster preferably comprises an acrylic adhesive and an inactive impermeable film support containing the buprenorphine (salt). n COPYRIGHT: (C)1992,JPO
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8637073-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011252020-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007500134-A
priorityDate 1989-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5760
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491494
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID446220
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411108
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406100
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416053110
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411109
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507876
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527877
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462328
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411107
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9848990
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406099
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644073
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2826
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423334
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426326933
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5324289
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644017
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421461

Total number of triples: 44.